Arizona Veterans Research Foundation and Young Blood Institute Collaborate on Alzheimer's Pilot Study
In a significant advance for Alzheimer's research, the Arizona Veterans Research and Education Foundation (AVREF), in collaboration with AmBARI Healthcare and the Young Blood Institute (YBI), has announced the launch of a clinical pilot study designed to explore innovative treatments for veterans battling cognitive impairments related to Alzheimer's disease. This partnership aims to assess the efficacy of a novel therapeutic plasma exchange (TPE) technique, particularly targeting veterans with mild cognitive impairment (MCI) and prodromal Alzheimer’s disease.
The pilot study, referred to as the AmBARI Study, will be conducted under the auspices of the Phoenix VA Health Care System and is poised to include up to 56 veteran participants. The focus will be on a specialized TPE protocol involving a complete plasma volume exchange, promising to shed new light on the brain's amyloid burden—a significant marker associated with Alzheimer's progression. The outcome will be evaluated through advanced imaging techniques, specifically PET-CT scans using a tracer substance known as NAV-4694, which allows researchers to quantify changes in the deposition of amyloid in the brain.
Leading the scientific investigation is Dr. S. Mitchell Harman, MD, PhD, who heads the team at the Phoenix VA. His comprehensive expertise and collaborative efforts with YBI, helmed by globally recognized researcher Dr. Colin Masters, promise to bring innovative approaches to Alzheimer’s treatment, building on encouraging results from previous studies.
Historically, both the Grifols-AMBAR study and clinical experiences from the Ace Alzheimer Center in Barcelona have shown promising results—exhibiting a 61% success rate in slowing or halting disease progression among patients with early to mid-stage Alzheimer’s. Additionally, 11 to 15% of subjects reported memory improvements through TPE interventions. With more than 2,100 TPE treatments having been administered under rigorous clinical protocols in Spain, the data supporting this approach is increasingly robust.
Compelling preclinical studies conducted by YBI further suggest that TPE has potential applications beyond those who are already showing cognitive decline, providing hope for broader therapeutic effects. Dr. Colin Masters emphasized the excitement surrounding the pilot study, highlighting its potential to substantiate the amyloid hypothesis and foster a deeper understanding of how key elements of human serum can actively interact with and remove amyloid-beta from the brain.
This groundbreaking initiative reflects a concerted effort to leverage advanced market technologies, including cutting-edge biomarker detection and imaging methodologies, to elevate the standards of medical care available to veterans. As noted by Elijah J. Ditter, Director of the Phoenix VA Medical Center, this clinical research collaboration stands as a vital stride toward making innovative, translational research accessible to veterans who are confronted with the challenges posed by this devastating disease.
Moreover, Dr. Samuel M. Aguayo from the Phoenix VA emphasized the institution’s strong track record of translating research into clinical practice. The CRADA (Cooperative Research and Development Agreement) underscores the commitment to bringing rigorous scientific exploration into the care continuum for veterans. Jeremy Greene, executive director of AVREF, elaborated that collaborations with research-centric organizations like YBI enhance the ability to deliver pioneering treatment options which can also translate to broader population benefits.
The governance of the study will be ensured through the oversight of the Institutional Review Board at the Phoenix VA, maintaining compliance with all relevant United States regulatory obligations. Moreover, this partnership enforces a public-private model that seeks to augment veterans' voices in refining their healthcare trajectories.
As the healthcare landscape continues to evolve, efforts like those from AVREF, YBI, and the Phoenix VA Health Care System signal a committed direction toward embracing collaboration in research to foster innovative solutions for age-related ailments like Alzheimer’s. The study represents both hope for advancing treatment options and a testament to the importance of supporting our veterans in their health journeys.
For additional information regarding this important study or to learn more about the organizations involved, please visit the official websites of the
Phoenix VA Health Care System and the
Young Blood Institute.